Barclays Maintains an 'Overweight' on Covidien Ltd (COV); Is This Your First Time?

Barclays maintains an 'Overweight' on Covidien Ltd (NYSE: COV) price target of $62.00.

Analyst, Matthew Taylor, offers a guidebook on what to expect at COV's Investor Meeting on Sept 13. The company should discuss market growth rates, market shares, and company initiatives at a level of granularity similar to prior years. Taylor also believes Covidien will give FY13 guidance for the first time and anticipate bracket street expectations on the top and bottom lines ($12.276 B; up 4%; $4.39; up 4%).

For an analyst ratings summary and ratings history on Covidien Ltd click here. For more ratings news on Covidien Ltd click here.

Shares of Covidien Ltd closed at $56.99 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• Cantor Fitzgerald Reiterates Overweight Rating on Applied Materials (AMAT)
• Powell Industries (POWL) PT Lowered to $235 at Cantor Fitzgerald